Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer

被引：0
|
作者：
Briones, Natalia [1 ]
Facista, Salvatore [1 ]
Halperin, Rebecca [1 ]
Heaton, Paul [2 ]
Mahadevan, Daruka [3 ]
Hendricks, Wiiliam [1 ]
Kim, Suwon [2 ]
机构：
[1] Translat Genom Res Inst, Phoenix, AZ USA
[2] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA
[3] Univ Arizona, Ctr Canc, Tucson, AZ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3412
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [2] A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer
    Jia, Luyao
    Ling, Yuwei
    Li, Kaifu
    Zhang, Lina
    Wang, Yajun
    Kang, Hua
    [J]. CLINICAL BREAST CANCER, 2021, 21 (06) : E654 - E664
  • [3] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    [J]. CANCER, 2010, 116 (12) : 2856 - 2867
  • [4] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    [J]. CANCER RESEARCH, 2012, 72
  • [6] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    [J]. JOURNAL OF ONCOLOGY, 2013, 2013
  • [7] The predictive value of the mature B cell signature in early Her2-positive breast cancer treated with neoadjuvant therapy
    Lin, Po-Han
    Lo, Chiao
    Kuo, Sung-Hsin
    Huang, Chiun-Sheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer
    Hendricks, William P. D.
    Briones, Natalia
    Halperin, Rebecca F.
    Facista, Salvatore
    Heaton, Paul R.
    Mahadevan, Daruka
    Kim, Suwon
    [J]. CANCERS, 2019, 11 (10)
  • [9] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    [J]. BREAST CARE, 2021, 16 (03)
  • [10] Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Kikuchi, M.
    Lino, Y.
    Takeyoshi, I.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 73 - 73
12345